NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 78 resultados LastUpdate Última actualización 11/08/2020 [14:25:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



previousPage Página2 de 4 nextPage   por página


IL6 GENE SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF DEVELOPING DRUG-INDUCED LEUKOPENIA AND METHOD FOR PREDICTING RISK OF LEUKOPENIA USING SAME

NºPublicación: WO2020153617A1 30/07/2020

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
SEOUL NAT UNIV HOSPITAL [KR]

Resumen de: WO2020153617A1

The present invention relates to a composition for predicting the risk of developing leukopenia comprising a single nucleotide polymorphism marker in an IL6 gene and a method for predicting the risk of developing leukopenia using same. As the single nucleotide polymorphism marker in an IL6 gene according to the present invention has a high correlation with the risk of developing leukopenia induced by drugs, in particular thiopurine-based drugs, patients with high susceptibility to leukopenia occurring during thiopurine-based drug treatment from leukemia, Crohn's disease, ulcerative colitis, or organ transplantation etc. can be effectively predicted or diagnosed by using the single nucleotide polymorphism marker at an early stage, and by administering a drug suitable for the patient through such prediction and diagnosis, it is possible to efficiently perform patient-specific treatment that can achieve an optimal treatment effect. Furthermore, the single nucleotide polymorphism marker according to the present invention can be utilized in drug development studies for the treatment of drug-induced leukopenia.

traducir

INHIBITORS OF PROTEIN KINASES

NºPublicación: US2020239458A1 30/07/2020

Solicitante:

PORTOLA PHARM INC [US]

US_2018186783_A1

Resumen de: US2020239458A1

The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

traducir

METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION

NºPublicación: US2020239963A1 30/07/2020

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]

JP_2016533742_A

Resumen de: US2020239963A1

Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a IIOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g., by quantitating the relevant RNA and comparing it to that of a healthy individual (or cell) or to a predetermined standard or it can be inferred by determining whether the patient or cell possesses a mutation that is associated with elevated HOX cluster gene or HOX cluster associated gene expression and thereby inferring that the relevant expression with be elevated.

traducir

METHODS AND COMPOSITIONS FOR USE OF TREX2 AS DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER

NºPublicación: US2020239969A1 30/07/2020

Solicitante:

UNIV TEXAS [US]

WO_2019079255_PA

Resumen de: US2020239969A1

Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.

traducir

PROGNOSTIC MARKER FOR MYELOPROLIFERATIVE NEOPLASMS

NºPublicación: US2020239961A1 30/07/2020

Solicitante:

ROUSSY INST GUSTAVE [FR]

WO_2016207405_A1

Resumen de: US2020239961A1

The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that predisposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF) secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.

traducir

COMBINATION THERAPY WITH A BET INHIBITOR AND A BCL-2 INHIBITOR

NºPublicación: US2020237779A1 30/07/2020

Solicitante:

HOFFMANN LA ROCHE [US]

CN_110891608_A

Resumen de: US2020237779A1

The present invention is directed to the combination therapy of multiple myeloma with a BET inhibitor and a Bcl-2 inhibitor.

traducir

METHODS OF TREATING MULTIPLE MYELOMA

NºPublicación: US2020239589A1 30/07/2020

Solicitante:

SANOFI SA [FR]

WO_2020160020_A1

Resumen de: US2020239589A1

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.

traducir

METHODS OF TREATING PRURIGO NODULARIS USING ANTI-IL-31RA ANTIBODY COMPOSITIONS

NºPublicación: US2020239581A1 30/07/2020

Solicitante:

ZYMOGENETICS INC [US]

WO_2006088855_A1

Resumen de: US2020239581A1

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

traducir

MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS

NºPublicación: US2020239593A1 30/07/2020

Solicitante:

AIMM THERAPEUTICS BV [NL]

ES_2729057_T3

Resumen de: US2020239593A1

The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

traducir

METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER

NºPublicación: EP3686290A2 29/07/2020

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
ST JUDE CHILDRENS RES HOSPITAL [US]

Resumen de: EP3686290A2

A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.

traducir

METHODS OF TREATING MULTIPLE MYELOMA

NºPublicación: CA3048198A1 28/07/2020

Solicitante:

SANOFI SA [FR]

METHOD FOR TREATING AN ACUTE MYELOID LEUKEMIA

NºPublicación: WO2020150326A1 23/07/2020

Solicitante:

PTC THERAPEUTICS INC [US]
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST [US]

Resumen de: WO2020150326A1

An aspect described herein includes a method for treating acute myeloid leukemia (AML) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule tubulin polymerization inhibitor compound. More particularly, another aspect described herein includes a method for treating acute myeloid leukemia in a subject in need thereof comprising, administering to the subject an effective amount of the small molecule tubulin polymerization inhibitor compound described herein in combination with a chemotherapeutic agent.

traducir

Use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-(S-methylsulfonimidoyl)methylpyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma

NºPublicación: AU2019221019A1 23/07/2020

Solicitante:

BAYER AG
BAYER PHARMA AG

Resumen de: AU2019221019A1

The present invention relates to the use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S- methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine (compound A), more particularly (+)5- Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2- amine (compound A ́), for treating diffuse large B-cell lymphoma (DLBCL), especially in germinal- centre B-cell type of diffuse large B-cell lymphoma and especially in diffuse large B-cell lymphoma which cells have an amplification or translocation of the MYC gene and/or BCL2 gene and/or an overexpression of MYC and/or BCL2.

traducir

POLYPEPTIDE HAVING EFFECT OF INHIBITING PROLIFERATION OF LEUKEMIA CELLS

NºPublicación: WO2020147176A1 23/07/2020

Solicitante:

NANJING FENGRUI BIOTECHNOLOGY CO LTD [CN]

Resumen de: WO2020147176A1

Disclosed is a polypeptide having an effect of inhibiting the proliferation of leukemia cells, and the present invention specifically relates to the use of a polypeptide in a drug for treating leukemia. The polypeptide consists of 37 amino acids, with the amino acid sequence thereof being Lys-Glu-Ser-Met-Asp-Ala-Asn-Lys-Pro-Thr-Lys-Asn-Leu-Pro-Leu-Lys-Lys-Ile-Pro-Cys-Lys-Thr-Ser-Ala-Pro-Ser-Gln-Ser-Phe-Phe-Ala-Arg-Asp-Asn-Thr-Ala-Asn, and the N-terminus of the polypeptide being connected with myristic acid. The polypeptide prepared by the present invention can enter the leukemia cells by connecting with the myristic acid, thereby achieving the effect of inhibiting the proliferation of the leukemia cells.

traducir

ANTI-CD33 ANTIBODY-GUIDED IMAGING AND TREATMENT OF ACUTE MYELOID LEUKEMIA

NºPublicación: US2020230265A1 23/07/2020

Solicitante:

HOPE CITY [US]

Resumen de: US2020230265A1

Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.

traducir

CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR

NºPublicación: US2020231595A1 23/07/2020

Solicitante:

PHARMACYCLICS LLC [US]

US_2020223856_A1

Resumen de: US2020231595A1

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

TREATMENT OF HEMATOLOGIC MALIGNANCIES WITH AN ANTI-CXCR4 ANTIBODY

NºPublicación: US2020231683A1 23/07/2020

Solicitante:

SQUIBB BRISTOL MYERS CO [US]

ES_2705001_T3

Resumen de: US2020231683A1

The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.

traducir

CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS

NºPublicación: US2020231650A1 23/07/2020

Solicitante:

MILLENNIUM PHARM INC [US]
MOLECULAR TEMPLATES INC [US]

WO_2020154531_A1

Resumen de: US2020231650A1

The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.

traducir

COMBINATION THERAPY USING A CD19-ADC AND RCHP

NºPublicación: US2020230254A1 23/07/2020

Solicitante:

SEATTLE GENETICS INC [US]

Resumen de: US2020230254A1

This invention relates to treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Specifically, the disclosure provides a method of treating a subject having DLBCL or FL, the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC), and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).

traducir

ANTI-CD38 BINDING DOMAINS

NºPublicación: US2020231696A1 23/07/2020

Solicitante:

MILLENNIUM PHARM INC [US]

WO_2020154540_A1

Resumen de: US2020231696A1

Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.

traducir

TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF

NºPublicación: US2020231649A1 23/07/2020

Solicitante:

HUTCHINSON FRED CANCER RES [US]

BR_112019005633_A2

Resumen de: US2020231649A1

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

traducir

Vitamin K2 compositions for the treatment of drug induced neuropathy

NºPublicación: AU2018389092A1 23/07/2020

Solicitante:

SYNERGIA LIFE SCIENCES PVT LTD [IN]

Resumen de: AU2018389092A1

The present invention provides the use of vitamin K2 compositions for the treatment of drug- induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug- induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.

traducir

Composition and method for treating peripheral T-cell lymphoma and cutaneous T-cell lymphoma

NºPublicación: AU2018378415A1 23/07/2020

Solicitante:

RHIZEN PHARMACEUTICALS SA [CH]

WO_2019111185_PA

Resumen de: AU2018378415A1

The present invention relates to the use of a dual selective PI3K delta and gamma protein kinase inhibitor, such as (S)-2-(1-((9H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one (Compound (A), also known as tenalisib) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing such an inhibitor for the treatment of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). 34 139095.00100/115268675v.1

traducir

Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds

NºPublicación: AU2018379713A1 23/07/2020

Solicitante:

NUCANA PLC [GB]

CA_3082269_A1

Resumen de: AU2018379713A1

The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.

traducir

SPECIFIC T CELL RECEPTORS AGAINST EPITOPES OF MUTANT MYD88L265P PROTEIN FOR ADOPTIVE T CELL THERAPY

Nº publicación: EP3683229A1 22/07/2020

Solicitante:

UNIV BERLIN CHARITE [DE]

Resumen de: EP3683229A1

The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a MYD88 L265P peptide of SEQ ID NO: 2 in the context of HLA-B*07:02 having a high avidity to said peptide/HLA complex. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, as well as the medical use of such nucleic acids, proteins or host cells, in particular, in the diagnosis, prevention and/or treatment of a MyD88 L265P expressing cancer such as a non-Hodgkin B-cell lymphoma selected from the group comprising diffuse large B-cell lymphoma (DLBCL), e.g., activated B-cell-like DLBCL (ABC-DLBCL) or pCNS DLBCL, cutaneous DLBCL, leg-type DLBCL or testicular DLBCL; lymphoplasmacytic lymphoma (LPL), e.g., Waldenstrom macroglobulinemia (WM); and IgM monoclonal gammopathy (IgM MGUS).

traducir

previousPage Página2 de 4 nextPage por página

punteroimgVolver